- Home
- LLAP vs CRVS Comparison
LLAP vs CRVS Comparison
Compare LLAP & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LLAP
- CRVS
- Stock Information
- Founded
- LLAP 2013
- CRVS 2014
- Country
- LLAP United States
- CRVS United States
- Employees
- LLAP N/A
- CRVS N/A
- Industry
- LLAP Military/Government/Technical
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- LLAP Industrials
- CRVS Health Care
- Exchange
- LLAP Nasdaq
- CRVS Nasdaq
- Market Cap
- LLAP 165.7M
- CRVS 161.4M
- IPO Year
- LLAP N/A
- CRVS 2016
- Fundamental
- Price
- LLAP $0.24
- CRVS $4.39
- Analyst Decision
- LLAP Buy
- CRVS Buy
- Analyst Count
- LLAP 3
- CRVS 3
- Target Price
- LLAP $2.58
- CRVS $5.75
- AVG Volume (30 Days)
- LLAP 9.2M
- CRVS 353.6K
- Earning Date
- LLAP 08-12-2024
- CRVS 08-06-2024
- Dividend Yield
- LLAP N/A
- CRVS N/A
- EPS Growth
- LLAP N/A
- CRVS N/A
- EPS
- LLAP N/A
- CRVS N/A
- Revenue
- LLAP $133,107,000.00
- CRVS N/A
- Revenue This Year
- LLAP $8.71
- CRVS N/A
- Revenue Next Year
- LLAP $34.59
- CRVS N/A
- P/E Ratio
- LLAP N/A
- CRVS N/A
- Revenue Growth
- LLAP 10.75
- CRVS N/A
- 52 Week Low
- LLAP $0.23
- CRVS $1.05
- 52 Week High
- LLAP $1.62
- CRVS $4.75
- Technical
- Relative Strength Index (RSI)
- LLAP 24.64
- CRVS 60.71
- Support Level
- LLAP $0.24
- CRVS $3.90
- Resistance Level
- LLAP $0.25
- CRVS $4.20
- Average True Range (ATR)
- LLAP 0.01
- CRVS 0.28
- MACD
- LLAP 0.02
- CRVS -0.07
- Stochastic Oscillator
- LLAP 2.10
- CRVS 31.82
About LLAP Terran Orbital Corporation
Terran Orbital Corp is a manufacturer of satellite products primarily serving the aerospace and defense industries. The company provide end-to-end satellite solutions by combining satellite design, production, launch planning, mission operations, and on-orbit support to meet the needs of our military, civil, and commercial customers. Geographically company operates in United States and Europe. Majority of the revenue is generated from United States.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).